Additional Iressa Study Closed Due To Lack Of Survival Benefit

Data monitoring committee recommends closing National Cancer Institute-sponsored trial studying gefitinib as a maintenance therapy in non-small cell lung cancer patients who responded to chemo. NCI trial is the second study in recent months in which Iressa failed to demonstrate a survival benefit.